Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.44 -2.0%	$1.99	$1.11 ▼ $5.00	$662.69M	1.81	1.56 million shs	952,057 shs
GALT Galectin Therapeutics	$2.85 +1.8%	$1.82	$0.73 ▼ $3.90	$177.22M	0.7	417,156 shs	204,499 shs
GYRE Gyre Therapeutics	$7.41 +3.5%	$8.70	$6.11 ▼ $19.00	$671.30M	1.72	129,670 shs	62,074 shs
MGTX MeiraGTx	$8.67 +1.2%	$6.33	$3.85 ▼ $8.98	$688.73M	1.24	405,548 shs	223,055 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-2.01%	-1.21%	+19.02%	+70.63%	-45.90%
GALT Galectin Therapeutics	+1.79%	+26.67%	+91.28%	+106.52%	+13.10%
GYRE Gyre Therapeutics	+3.49%	-7.38%	-7.72%	-16.55%	-52.83%
MGTX MeiraGTx	+1.17%	+3.58%	+30.97%	+60.26%	+78.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.6676 of 5 stars	3.5	1.0	0.0	2.8	3.3	0.6
GALT Galectin Therapeutics	2.2471 of 5 stars	3.5	2.0	0.0	3.3	1.7	0.0
GYRE Gyre Therapeutics	0.1217 of 5 stars	0.0	1.0	0.0	2.2	0.8	0.0
MGTX MeiraGTx	4.2499 of 5 stars	3.5	1.0	4.8	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	281.97% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	110.53% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
MGTX MeiraGTx	3.00	Buy	$24.00	176.82% Upside

Current Analyst Ratings Breakdown

Latest GALT, MGTX, GYRE, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	64.17	N/A	N/A	$1.61 per share	1.52
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
GYRE Gyre Therapeutics	$105.76M	6.57	$0.20 per share	36.25	$1.05 per share	7.06
MGTX MeiraGTx	$33.28M	20.94	N/A	N/A	$0.87 per share	9.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/14/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	370.69	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	22.82	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)

Latest GALT, MGTX, GYRE, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/12/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	N/A	N/A	N/A	$30.80 million	N/A
8/11/2025	Q2 2025	MGTX MeiraGTx	-$0.52	N/A	N/A	N/A	$8.00 million	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
GALT Galectin Therapeutics	N/A	0.08	0.08
GYRE Gyre Therapeutics	N/A	3.60	3.19
MGTX MeiraGTx	2.34	1.53	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
GALT Galectin Therapeutics	11.68%
GYRE Gyre Therapeutics	23.99%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
GALT Galectin Therapeutics	50.10%
GYRE Gyre Therapeutics	10.00%
MGTX MeiraGTx	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable

GALT, MGTX, GYRE, and AUTL Headlines

Recent News About These Companies

MeiraGTx (NASDAQ:MGTX) Hits New 12-Month High - Here's What Happened

July 16 at 6:20 AM | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Down - What's Next?

July 11, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Sets New 1-Year High - Here's Why

July 10, 2025 | marketbeat.com

MeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past week

July 9, 2025 | finance.yahoo.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) CEO Alexandria Forbes Sells 47,500 Shares

July 8, 2025 | marketbeat.com

Insider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLC

July 8, 2025 | gurufocus.com

MeiraGTx (NASDAQ:MGTX) Rating Increased to Hold at Wall Street Zen

July 5, 2025 | marketbeat.com

MeiraGTx Holdings PLC News (MGTX) - Investing.com

July 3, 2025 | investing.com

MeiraGTx Holdings plc (MGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

MeiraGTx (NASDAQ:MGTX) Stock Price Up 7.8% - Here's Why

July 2, 2025 | marketbeat.com

42,115 Shares in MeiraGTx Holdings PLC (NASDAQ:MGTX) Purchased by Acuitas Investments LLC

July 2, 2025 | marketbeat.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) Shares Acquired by Janney Montgomery Scott LLC

July 1, 2025 | marketbeat.com

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27, 2025 | zacks.com

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025 | globenewswire.com

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025 | globenewswire.com

FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment

May 10, 2025 | investing.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 9, 2025 | finance.yahoo.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025 | globenewswire.com

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

April 29, 2025 | globenewswire.com

Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

April 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, MGTX, GYRE, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.44 -0.05 (-2.01%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.50 +0.06 (+2.46%)

As of 09:06 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Galectin Therapeutics NASDAQ:GALT

$2.85 +0.05 (+1.79%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.80 -0.04 (-1.58%)

As of 09:01 AM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Gyre Therapeutics NASDAQ:GYRE

$7.41 +0.25 (+3.49%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$7.42 +0.01 (+0.13%)

As of 08:00 AM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

MeiraGTx NASDAQ:MGTX

$8.67 +0.10 (+1.17%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$8.68 +0.01 (+0.12%)

As of 07:00 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time